Adrian W. Quartel - 21 Feb 2022 Form 4 Insider Report for Acer Therapeutics Inc.

Role
Chief Medical Officer
Signature
/s/ Harry S. Palmin, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
21 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 15:39:34 UTC
Next filing
16 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACER Employee Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 21 Feb 2022 Common Stock 200,000 $2.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable over four years as follows: 25% of the shares vest on February 21, 2023, and the remaining 75% of the shares vest quarterly over the remainng three years.